Market for Kinase Inhibitors to treat cancer will reach $31.16bn in 2019, says new visiongain report

 
 
vg
vg
LONDON - Nov. 17, 2015 - PRLog -- (PHA0061) Press release text for Kinase Inhibitors for Cancer Treatment: World Industry Analysis, R&D and Market Forecasts 2015-2025 - Explore the Potentials of New Drugs

Market for kinase inhibitors to treat cancer
will reach $31.16bn in 2019, according to new visiongain data

A new report by visiongain forecasts that overall sales of kinase inhibitor drugs for treating cancer will achieve revenues of $31.16 billion in 2019. Those sales will expand from 2015 to 2025 as the loss of market exclusivity is outweighed by the entry of new treatments. That revenue prediction and others appear in Kinase Inhibitors for Cancer Treatment: World Industry Analysis, R&D and Market Forecasts 2015-2025 - Explore the Potentials of New Drugs, published in August 2015.

Visiongain is a business information publisher and consultancy in London, UK. Its purpose is to help organisations understand commercial prospects of industries and markets in healthcare and other fields.

That updated study analyses events, prospects and sales opportunities shaping the development, production and marketing of anti-cancer kinase inhibitor therapies. The analysis shows multilevel revenue forecasting and qualitative assessments. The work also explores activities of leading companies providing those medicines, assessing their potentials from 2015.That pharmaceutical market holds many commercial opportunities, including potential for personalised medicine.

Visiongain’s survey predicts that rapid expansion of revenues in the anti-cancer kinase inhibitor market will cease between 2019 and 2025. A contributor to that slowing will be expiration of patents on some leading kinase inhibitors, including Pfizer’s Sutent (sunitinib), Bristol-Myer Squibb’s Sprycel (dasatinib) and Novartis’ Afinitor (everolimus). The overall compound annual growth rate for the forecast period will be 6%. Some sectors of the market will show rapid growth, as they serve under-met needs in cancer medicine.

In 2014, the Bcr-Abl tyrosine-kinase inhibitor submarket formed the most lucrative part of that industry, accounting for 43.2% of the overall world market. However, the study shows that segment will shift in market share over the forecast period and that other kinase inhibitor sectors will overtake it by the end of the forecast period. That shift will be due to demand for innovative targeted therapies and expiry of patent protection on Bcr-Abl kinase drugs.

Mashael Zaidi, a pharmaceutical industry analyst in visiongain, said: “The anti-cancer kinase inhibitor market is garnering a lot of interest from companies at the moment, and justly so, as kinase inhibitors represent a great deal of potential advancement in cancer treatment. Kinase inhibition is a very promising area of research, as it can offer targeted therapy with limited damage of healthy tissue, which could potentially reduce adverse effects of cancer treatment while optimising the benefit. There is also high demand for personalised cancer treatment options, even in emerging markets, as living standards improve. Currently, the kinase inhibitor market is growing rapidly as cancer prevalence increases and demand for treatment rises. The aged population is also rising and, with that, will come a rise in the number of older patients who will need treatment for serious conditions, such as cancer, over longer lifetimes. This demand will stimulate the kinase inhibitor drug market. And further research and development on those medicines can lead to innovative and vital cancer treatments.”

Visiongain’s new investigation shows revenue predictions at overall world market, submarket, company, product and national level.

That work’s overarching analysis gives revenue forecasts to 2025 for eight submarkets at world level:

·         Bcr-Abl tyrosine-kinase inhibitors (TKI)

·         Angiogenesis inhibitors

·         EGFR inhibitors

·         mTOR inhibitors

·         BRAF and MEK inhibitors

·         Other kinase inhibitors

·         Pipeline drugs

·         Generics and other agents.

The study also shows revenue predictions to 2025 for 28 marketed products, including these drugs:

·         Glivec (imatinib)

·         Sprycel (dasatinib)

·         Tasigna (nilotinib)

·         Tarceva (erlotinib)

·         Nexavar (sorafenib)

·         Sutent (sunitinib)

·         Afinitor (everolimus)

·         Imbruvica (ibrutinib).

That survey also gives profiles for 23 medicines in development, with revenue forecasts for seven leading drug candidates.

In addition, the analyses cover prominent national markets for anti-cancer kinase inhibitor sales, with revenue forecasts to 2025 for these 11 countries:

·         United States (US)

·         Japan

·         Germany, France, United Kingdom (UK), Italy and Spain, also with overall EU prediction

·         Brazil, Russia, India and China (BRIC nations).

That survey examines leading pharmaceutical companies in that market. The work discusses mergers and acquisitions, collaborations and R&D, also forecasting revenues to 2025 for seven organisations:

·         Novartis

·         Pfizer

·         Roche

·         Bristol-Myers Squibb

·         Bayer

·         AstraZeneca

·         Gilead Sciences.

The study also shows two interviews by visiongain with other authorities on cancer-treating kinase inhibitors.

Kinase Inhibitors for Cancer Treatment: World Industry Analysis, R&D and Market Forecasts 2015-2025 adds to visiongain’s reports on industries and markets in healthcare. That portfolio covers pharmaceuticals, medical devices, diagnostics and outsourced services, including contract research (CROs), manufacturing (CMOs) and selling (CSOs).

Contact
Sara Peerun
***@visiongainglobal.com
End
Source: » Follow
Email:***@visiongainglobal.com Email Verified
Tags:Cancer, Kinase, Drugs
Industry:Business
Location:London City - London, Greater - England
Subject:Reports
Account Phone Number Verified     Disclaimer     Report Abuse
Visiongain PRs
Trending News
Most Viewed
Top Daily News



Like PRLog?
9K2K1K
Click to Share